Knowledge on rare diseases and orphan drugs
COVID-19 & Rare diseases
Rare Diseases Resources for Refugees/Displaced Persons
Search for a rare disease
Naxos disease
A rare arrhythmogenic right ventricular cardiomyopathy (ARVC) and a cutaneous phenotype, characterized by peculiar woolly hair and palmoplantar keratoderma.
ORPHA:34217
Classification level: Disorder
- KWWH type I
- Keratoderma with woolly hair type I
- Keratosis palmoplantaris with arrythmogenic cardiomyopathy
- Palmoplantar hyperkeratosis with arrythmogenic cardiomyopathy
- Palmoplantar keratoderma with arrythmogenic cardiomyopathy
- Naxos syndrome
Prevalence: Unknown
Inheritance: Autosomal recessive
Age of onset: Infancy, Neonatal
Naxos disease was first described in families originating from the Greek island of Naxos. Moreover, affected families have been identified in other Aegean islands, Turkey, Israel, Saudi Arabia, India, Argentina and French-Canadian families. A syndrome with the same cutaneous phenotype and predominantly left ventricular involvement has been described in families from India and Ecuador (carvajal syndrome).
Woolly hair appears from birth, palmoplantar keratoderma develop during the first year of life and cardiomyopathy is clinically manifested by adolescence with 100% penetrance. Patients present with syncope, sustained ventricular tachycardia or sudden death. Symptoms of right heart failure appear during the end stages of the disease.
Mutations in the JUP gene encoding the desmosomal proteins plakoglobin and desmoplakin have been identified as the cause of Naxos disease. Defects in the linking sites of these proteins can interrupt the contiguous chain of cell adhesion, particularly under conditions of increased mechanical stress or stretch, leading to cell death, progressive loss of myocardium and fibro-fatty replacement.
Diagnosis is suspected on clinical presentation based on palmoplantar keratoderma with hair shaft abnormalities, mostly of woolly hair type present from infancy, fulfilling the diagnostic criteria of ARVC later in adolescence or early adulthood. It is confirmed by the presence of a JUP variant in homozygosity on genetic testing.
Naxos disease should be differentiated from carvajal syndrome that is caused by homozygous variants in desmoplakin (DSP), clinically manifested during childhood and leading more frequently to heart failure. It presents with similar cutaneous features as those of Naxos disease, in infancy, but the cardiac phenotype is compatible with arrhythmogenic cardiomyopathy with left ventricular predominance.
Antenatal diagnosis is possible where the pathogenic variant has previously been identified in a family member.
Naxos disease transmission is autosomal recessive. If both individuals are carriers of the disease-causing variant, there is a 25% risk of having an affected child at each pregnancy. Therefore it is recommended that genetic counseling be offered to at-risk couples.
Implantation of an automatic cardioverter defibrillator is indicated for prevention of sudden cardiac death. Antiarrhythmic drugs are used for preventing recurrences of episodes of sustained ventricular tachycardia and classical pharmacological treatment for congestive heart failure, while heart transplantation is considered at the end stages.
Prognosis in Naxos disease tracks that of other genetic cases of ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy). Patients are at risk of developing life-threatening arrhythmias and heart failure.
Last update: August 2023 - Expert reviewer(s): Dr Alexandros PROTONOTARIOS - Dr Adalena TSATSOPOULOU
: produced/endorsed by ERN(s)
: produced/endorsed by FSMR(s)
Guidelines
Disease review articles
Genetic testing
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
- Research project(s) (45)
- Clinical trial(s) (3)
- Biobank(s) (10)
- Registry(ies) (26)
- Network of experts (6)
Newborn screening